Regulatory press releases

Nanologica’s Annual Report 2022 Published

24 March, 2023

Nanologica AB’s annual report for 2022 is now published on the company’s website. The annual report in Swedish, and an English translation, is available on www.nanologica.com as a pdf. The annual report in Swedish is also available in the European Single Electronic Format (ESEF). Swedish: https://nanologica.com/category/finansiella-rapporter/ English translation: https://nanologica.com/category/financial-reports/ For further information, please contact: Johanna Johansson, Director IR, Communications and Marketing Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com This information is information that

Nanologica’s Year-End Report 2022

10 February, 2023

FINANCIAL SUMMARY Net sales for the fourth quarter amounted to TSEK 674 (676) and for the full year to TSEK 1,555 (12,914) The operating loss for the quarter amounted to TSEK -13,251 (-14,108) and for the full year to TSEK -50,850 (-40,689) Loss after tax for the quarter amounted to TSEK -14,855 (-15,222) and for the full year to TSEK -55,231 (-44,829) Earnings per share before and after dilution were SEK -0.42 (-0.54) for the

Nanologica’s Interim Report Jan-Sep 2022

11 November, 2022

Nanologica AB’s Interim Report Jan-Sep 2022 The auditor’s report Q3 2022 (Swedish) Report presentation Q3 2022 FINANCIAL SUMMARY Net sales for the third quarter amounted to TSEK 401 (2,119) and for the nine-month period to TSEK 881 (12,238) The operating result for the quarter amounted to TSEK -9,610 (-11,718) and for the nine-month period to TSEK -37,599 (-26,581) Result after tax for the quarter amounted to TSEK -10,988 (-12,546) and for the nine-month period

Nanologica’s Rights Issue Registered – Conversion of BTA to Shares

8 November, 2022

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Nanologica AB’s (publ) rights issue of shares that ended on October 5, 2022 has today been registered with the Swedish Companies Registration Office. The

Change of Number of Shares in Nanologica AB (publ)

31 October, 2022

The number of shares and votes in Nanologica AB (publ) has changed during the month of October as a result of the completion of the previously communicated preferential rights issue. As previously communicated, Nanologica’s board of directors on August 23, 2022, decided on a new share issue of approximately MSEK 94 with preferential rights for existing shareholders, in order to finance intensified investments in preparative chromatography. On October 10, Nanologica announced that the rights issue

Nanologica Announces Nomination Committee for the Annual General Meeting 2023

20 October, 2022

In accordance with the resolution at the Annual General Meeting (“AGM”) on June 2, 2022, the chairman of the board has contacted the company’s three largest owners or ownership groups in terms of votes as of September 30, 2022, each of whom has appointed a representative to constitute the nomination committee of Nanologica AB for the 2023 AGM. The nomination committee for Nanologica AB’s 2023 AGM thus consists of the following three members: Carl-Johan Spak

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.